Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605927 · ClinicalTrials.gov registry record · Phase 1
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT03605927 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 45 participants.
The verdict
NCT03605927, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.
Interventions
- DRUG Sirolimus
- DRUG Tacrolimus
- DRUG BMS-986004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605927
The ClinicalTrials.gov registry entry for NCT03605927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sirolimus is the first listed.
NCT03605927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605927 about?
NCT03605927 is a clinical study titled "CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease". The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.
What is the current status of trial NCT03605927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2019-02-15. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT03605927?
The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG), BMS-986004 (DRUG).
Who is sponsoring clinical trial NCT03605927?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.